What Is GLP-1? The Hormone, the Drugs, and Why They Work
GLP-1 explained: the natural hormone, receptor-agonist drugs (Ozempic, Wegovy, Mounjaro, Zepbound), dual/triple agonists, side effects, eligibility, cost ranges and pipeline.
- Published
- May 15, 2026
- Last reviewed
- August 8, 2026
- Reading time
- 7 min read
Educational only — not medical advice.
GLP-1 is, technically, a short peptide hormone your gut releases after you eat. Practically, it is the molecule family behind Ozempic, Wegovy, Mounjaro, Zepbound and the wave of medicines that reshaped obesity and diabetes care from the mid-2010s onward.
This is the cluster pillar for PeptideStat’s GLP-1 coverage: the natural hormone, the agonist drugs, what they do, who they are labeled for, and what they are not. Drug-specific pages link back here so status and mechanism stay consistent.
Short answer: Natural GLP-1 is a short-lived gut signal. GLP-1 receptor agonists are engineered medicines that keep that signal on longer — improving glucose control and reducing appetite for many people under medical care.
Related maps: peptides for weight loss · semaglutide vs tirzepatide · GLP-1 side effects · what are peptides.
The hormone
GLP-1 (glucagon-like peptide-1) is an incretin — a hormone released by intestinal L-cells when food arrives in the gut. It does several things:
- Stimulates insulin release (glucose-dependent) — pancreatic beta cells release more insulin when blood sugar is rising
- Suppresses glucagon — reducing the liver’s release of stored sugar
- Slows gastric emptying — food leaves the stomach more slowly, which extends satiety
- Acts on appetite centers in the brain — reducing hunger and “food noise”
- Decreases caloric intake as a downstream effect
Natural GLP-1 has a half-life on the order of minutes — it is broken down quickly by enzymes such as DPP-4. That is why a hormone with useful effects did not become a weekly shot until chemists engineered longer-acting versions.
The drugs: GLP-1 receptor agonists
A GLP-1 receptor agonist is a synthetic molecule that mimics natural GLP-1 but is built to resist rapid breakdown and stay active for hours or days.
| Active ingredient | Brand examples | Receptor class | Common labeled uses (check current USPI) |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | GLP-1 | T2D (Ozempic/Rybelsus); chronic weight management and other labeled uses (Wegovy) |
| Tirzepatide | Mounjaro, Zepbound | GIP + GLP-1 | T2D (Mounjaro); chronic weight management / obesity-related labels (Zepbound) |
| Liraglutide | Victoza, Saxenda | GLP-1 | T2D (Victoza); chronic weight management (Saxenda) |
| Dulaglutide | Trulicity | GLP-1 | Type 2 diabetes |
| Exenatide | Byetta, Bydureon | GLP-1 (shorter-acting roots) | Type 2 diabetes |
Do not mix brands casually. Ozempic and Wegovy both contain semaglutide but are labeled and dosed for different indications. Mounjaro and Zepbound both contain tirzepatide with the same kind of split. Details: Ozempic vs Wegovy · Zepbound vs Wegovy.
Dual and triple agonists (still “in the GLP-1 conversation”)
Marketing language often calls everything a “GLP-1.” More precise:
| Design | Receptors | Status snapshot | Guide |
|---|---|---|---|
| Single agonist | GLP-1 | Multiple approved products | This page + brand guides |
| Dual agonist | GIP + GLP-1 | Tirzepatide approved | Semaglutide vs tirzepatide |
| Triple agonist | GIP + GLP-1 + glucagon | Retatrutide investigational | Retatrutide |
How GLP-1 agonists work for weight loss
When a long-acting agonist is on board:
- Receptors stay activated longer than native GLP-1 would allow
- Satiety signals arrive earlier in meals for many people
- “Food noise” often quiets — a common patient-reported change
- Average caloric intake falls in trials
- Average weight loss depends on the molecule and dose
Approximate trial-average anchors (not personal guarantees):
| Program pattern | Rough average weight change | Horizon |
|---|---|---|
| Semaglutide obesity programs (e.g. STEP 1) | ~15% at higher maintenance dose | ~68 weeks |
| Tirzepatide obesity programs (e.g. SURMOUNT-1) | up to ~21% at highest dose arms | ~72 weeks |
| Retatrutide Phase 2 obesity | ~24% at 12 mg | 48 weeks (investigational) |
Head-to-head detail: semaglutide vs tirzepatide. Pipeline context: tirzepatide vs retatrutide.
Side effects, in plain terms
GLP-1-class side effects are often predictable, dose-related and mostly gastrointestinal, especially during escalation:
- Nausea, vomiting, diarrhea, constipation, reflux
- Appetite reduction that can overshoot protein/calorie needs
- Injection-site reactions
- Gallbladder events associated with rapid weight loss
- Rare but serious: pancreatitis signals — medical emergency
- Class thyroid C-cell warning from rodent data (MTC / MEN 2 contraindications on labels)
- Lean-mass loss can accompany large total weight loss
Full safety page: GLP-1 side effects. Muscle context: GLP-1 muscle loss.
Who qualifies (label framing)
Weight-management products (e.g. Wegovy, Zepbound, Saxenda) generally use criteria on the order of:
- BMI ≥ 30, or
- BMI ≥ 27 with at least one weight-related condition
Diabetes products (e.g. Ozempic, Mounjaro, Trulicity, Rybelsus) require a type 2 diabetes diagnosis on label. Exact wording and extra indications (CV risk, OSA, etc.) belong on the current prescribing information, not on social media.
Who often needs careful clinician review
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Severe gastroparesis
- Pregnancy or planned pregnancy
- Active or recent eating disorders
- Type 1 diabetes (different disease; not a general T1D treatment class)
This is not an exhaustive contraindication list — labels and clinicians decide.
Cost and access ranges (order-of-magnitude)
Access often drives the real choice more than trial averages:
- Commercial insurance + manufacturer support: can be low monthly cost for some
- Manufacturer direct / cash programs: hundreds per month in many public programs
- Brand list price without support: often near four figures monthly
- Compounded or research products: different risk and legal framing entirely
Literacy pages: GLP-1 cost · cheapest GLP-1 for weight loss · GLP-1 coupon.
What GLP-1 is not
- Not insulin. Agonists can increase glucose-dependent insulin release; they are not insulin products.
- Not growth hormone. Sermorelin and secretagogues are a different class.
- Not “a GLP-1 inhibitor.” That search phrase is usually a mix-up with agonists or with SGLT2 inhibitors — GLP-1 vs SGLT2.
- Not berberine or supplement stacks. Marketing “natural GLP-1” claims do not equal prescription agonist efficacy.
What happens when you stop
Many people regain a large share of lost weight after discontinuation if no durable behavior and medical plan remains. Related evidence for tirzepatide withdrawal (SURMOUNT-4) is a class-adjacent warning, not a unique moral failure of patients. Obesity is chronic for many people; labels and guidelines treat therapy duration accordingly.
Pipeline next to watch
- Retatrutide — triple agonist; see retatrutide
- CagriSema (cagrilintide + semaglutide) — see CagriSema
- Oral non-peptide agonists (e.g. orforglipron-class development) — different chemistry, same metabolic conversation
Practical tools (math only)
If you are only checking unit math for research literacy:
Database profiles: semaglutide · tirzepatide · retatrutide.
Bottom line
GLP-1 is a short-lived gut hormone. Modern “GLP-1 drugs” are longer-acting receptor agonists — and related dual/triple designs — with large trial effects on weight and glucose for appropriate patients. The useful next click is almost never “more hype”; it is the specific drug page, the side-effect map, and a clinician who can match label, history and access.
References
Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM.
Novo Nordisk. Wegovy prescribing information.
Eli Lilly. Zepbound prescribing information.
Direct answers
Frequently asked questions
Is GLP-1 the same as Ozempic?
No. GLP-1 is the natural hormone. Ozempic is a brand name for semaglutide, a GLP-1 receptor agonist drug.
What does GLP-1 stand for?
Glucagon-like peptide-1.
Is there a natural way to increase GLP-1?
Protein- and fiber-rich meals modestly raise endogenous GLP-1. Supplements marketed as “GLP-1 boosters” do not replicate prescription agonist drugs.
How long does it take to see GLP-1 weight loss?
Appetite changes often appear in the first 1–2 weeks. Meaningful weight loss commonly shows by 6–8 weeks; trial averages are measured over many months.
Is tirzepatide a GLP-1?
Tirzepatide activates GLP-1 and GIP receptors. It is usually discussed with GLP-1 medicines but is technically a dual agonist.
What happens when you stop a GLP-1?
Many people regain a substantial share of lost weight after stopping. Obesity treatment is often framed as long-term care, not a short course.
Who qualifies for weight-management GLP-1s?
Label criteria typically include BMI ≥30, or BMI ≥27 with a weight-related condition. Exact criteria are on each product label and require clinician judgment.
Filed under